[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
作者信息
Heinzl Susanne
出版信息
Med Monatsschr Pharm. 2006 Mar;29(3):93-6.
PMID:16550882
Abstract
摘要
相似文献
1
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Med Monatsschr Pharm. 2006 Mar;29(3):93-6.
2
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Diabetes Care. 2007 Jun;30(6):1344-50. doi: 10.2337/dc07-0233. Epub 2007 Mar 2.
3
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Med Monatsschr Pharm. 2007 Aug;30(8):282-6; quiz 287-8.
4
DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Int J Clin Pract. 2006 Nov;60(11):1454-70. doi: 10.1111/j.1742-1241.2006.01178.x.
5
MK-431 (Merck).
Curr Opin Investig Drugs. 2005 Apr;6(4):419-26.
6
New treatments for diabetes.
N Engl J Med. 2007 May 24;356(21):2221; author reply 2222-3.
7
New treatments for diabetes.
N Engl J Med. 2007 May 24;356(21):2222; author reply 2222-3.
8
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Dtsch Med Wochenschr. 2008 Oct;133(43):2233-7. doi: 10.1055/s-0028-1091266. Epub 2008 Oct 15.
9
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Pharmacotherapy. 2007 Aug;27(8):1163-80. doi: 10.1592/phco.27.8.1163.
10
[DPP-4 inhibition raises incretin levels].
Med Monatsschr Pharm. 2006 Aug;29(8):311-2.
Zotero 插件